Metastasis-free survival as a surrogate endpoint in prostate cancer clinical trials

As many readers will have realized, the major regulatory authorities started, some time ago, to accept prostate cancer progression-free survival of differing types as a surrogate for overall survival in the approval of some drugs for the treatment of prostate cancer. … READ MORE …

The TOAD trial: follow-up data on quality of life

Some 15 months ago, we reported the initial, primary results of the TOAD trial, which showed an overall survival benefit for immediate as opposed to delayed initiation of androgen deprivation therapy (ADT) in non-metastatic patients considered to be inappropriate for curative therapy. … READ MORE …

“Discussing overdiagnosis is good science”

The term “over-diagnosis” didn’t exist 15 years ago in the management of prostate cancer. (Well, actually it did, but it would very rarely — if ever — have come to the notice of any patient or even of the average urologist or primary care physician.) … READ MORE …

Prostate cancer and treatment with immune checkpoint inhibitors

Immune checkpoint inhibitors include drugs like ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and others that can have dramatic effects on the survival of some groups of patients with advanced forms of some cancers. … READ MORE …

Are genomic tests “up to snuff” for routine use in prognosis of prostate cancer risk?

The Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) has just published a review of the available evidence on the clinical validity and utility of six prognostic biomarkers available for the assessment of prostate cancer-related risk. … READ MORE …

Carbon-11-labeled sarcosine as a prostate cancer imaging agent

A new paper in the Journal of Nuclear Medicine has reported the first use of [11C]sarcosine in combination with PET/CT scanning as a technique for imaging prostate cancer in man. … READ MORE …

Primary ADT in treatment of elderly men with organ-confined prostate cancer

One really has to wonder whether we are still treating elderly men, initially diagnosed with organ-confined prostate cancer, with first-line or “primary” androgen deprivation therapy ADT)! And if we are, why on Earth is that? … READ MORE …